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Abstract
The present study aimed at assessing the health-related quality of life (HRQoL) of patients with type 1
diabetes mellitus (DM1) submitted to autologous hematopoietic stem cell transplantation (HSCT). This
study is part of a pioneering research protocol which tests the applicability of autologous hematopoietic
stem cell transplantation as a new therapeutic approach to DM1. The study was conducted on 14 patients
admitted to the ward of the Bone Marrow Transplantation Unit of a university hospital during the period
from October 2006 to December 2007. The patients were evaluated at admission and on the occasion of the
ambulatory return visit 100 days after transplantation. They answered the SF-36 quality of life questionnaire
and the data were analyzed according to literature recommendations. The results showed that 100 days after
transplantation the value of the patients’ quality of life was higher compared to the pre-HSCT value, with
significant differences in the Physical Domains (Role Limitations due to Physical Problems) (p = .009),
Vitality (p = .02) and Mental Health (p = .04), demonstrating significant appreciation of those domains after
the procedure. The results indicate an improvement in HRQoL after HSCT. The SF-36 proved to be a
useful instrument for the assessment of quality of life in patients with DM1 submitted to HSCT.
Keywords: Type 1 Diabetes Mellitus; Quality of Life; Bone Marrow Transplantation; Hematopoietic
Stem Cells.
Resumo
Este estudo teve como objetivo avaliar a qualidade de vida relacionada à saúde (QVRS) de pacientes com
diabetes mellitus tipo 1 (DM1) submetidos ao Transplante de Células-Tronco Hematopoéticas (TCTH). O
estudo é parte de um protocolo de pesquisa pioneiro no mundo, que testa a aplicabilidade do TCTH como
nova abordagem terapêutica no DM1. Foram investigados 14 pacientes, que constituíram a população de
pessoas internadas na enfermaria da Unidade de Transplante de Medula Óssea de um hospital universitário,
no período de outubro de 2006 a dezembro de 2007. Os pacientes foram avaliados na admissão e no
retorno ambulatorial 100 dias pós-transplante com o questionário de qualidade de vida SF-36. Os resultados
mostraram que, 100 dias após o transplante, a qualidade de vida apresentou valores superiores ao pré-
TCTH, com diferenças significantes nos Aspectos Físicos (p = 0,009), Vitalidade (p = 0,02) e Saúde
Mental (p = 0,04), evidenciando significativa apreciação nesses domínios após o procedimento. Os resultados
sugerem que houve melhora na QVRS pós-TCTH.
Palavras-chave: Diabetes Mellitus Tipo 1; Qualidade de Vida; Transplante de Medula Óssea; Células-
Tronco Hematopoéticas.
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The Multiple Facets of Diabetes Mellitus:
Etiopathogeny, Symptomatology and Epidemiology
Diabetes mellitus (DM) is diagnosed in the presence of
a reduction or alteration of the insulin produced by the
pancreas and is characterized by chronic hyperglycemia
with disorders of carbohydrate, lipid and protein meta-
bolism (Santos & Enumo, 2003), and is classified accor-
ding to its etiology. Type 1 diabetes mellitus (DM1) is
characterized by the destruction of beta cells, with
absolute insulin deficiency. Type 2 diabetes mellitus
(DM2) varies between insulin deficiency and a secretory
defect (F. P. M. Guimarães & Takayanagui, 2002).
The signs and symptoms of DM are: polydipsia
(excessive thirst), polyuria (excessive urine volume),
polyphagia (excessive hunger), rapid weight loss and
elevated hyperglycemia or glycosuria detected by routine
blood tests. Fasting glycemia between 100 and 125 mg/
dl is considered to represent glucose intolerance and two
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tests above 126 mg/dl are a criterion for the diagnosis of
DM. The most frequent complications of the disease are:
hypoglycemia, diabetic ketoacidosis, proteinuria, peri-
pheral neuropathy, retinopathy, and nephropathy, among
others (American Diabetes Association, 2005).
The World Health Organization ([WHO], 2004)
estimates at 143 million the number of persons with DM
worldwide and the projection for the year 2025 is that
the disease will reach 300 million individuals. In Brazil,
according to Health Ministry estimates, there are appro-
ximately five million people with DM, 90% of them with
type 2 and 5-10% with type 1 DM (Lojudice & Sogayar,
2008).
According to the Brazilian Diabetes Society (2007), the
lack of effective forms of prevention of DM1 cause this
disease to be one of the most important public health
problems, affecting people when they are completely
unprepared for the possibility of being diagnosed. This
element of surprise regarding the diagnosis of DM1, which
is a serious disease of chronic and degenerative course,
generates an initial commotion not only in the affected
person, but also in his family network, requiring a rearran-
gement of eating habits and life style. A rearrangement of
family relationships frequently occurs in order to provide
the necessary care to the patient (Zanetti, Biaggi, Santos,
Peres, & Teixeira, 2008).
Long-term complications usually arouse the greatest
fear in patients who receive a diagnosis of DM1, since
they know that, even if they rigorously follow the
conventional treatment, they will not be free from these
complications, which may arise sooner or later. It should
be remembered that 12 to 13% of patients are estimated
to die 20 years after the diagnosis, this being the fourth
cause of death in Brazil (Santos & Enumo, 2003).
The belief that treatment may be ineffective, allied to
the side effects of the disease and the almost total absence
of symptoms, impairs adhesion to treatment, which in
many cases only occurs due to the threat of future compli-
cations (Gimenes, Zanetti, & Haas, 2009; Marcelino &
Carvalho, 2005). Among adolescents the question is even
more complex since DM1 may cause limitations of inter-
personal relationships, with consequent difficulties of
socialization and insertion in the peer group, a fundamen-
tal task for individual development in this age range
(Imoniana, 2006). During adolescence, metabolic control
tends to deteriorate due to the decline in insulin production
that occurs because of the hormonal changes typical of
this age range, associated with insulin resistance, a greater
risk of hypoglycemia and difficulty in complying with
the treatment recommended by health professionals
(Damião & Pinto, 2007).
The treatment of DM, both type 1 and type 2, is quite
demanding because it imposes on the patient a full
restructuring of life habits (Zanetti et al., 2006). The
necessary care is based on three major factors, i.e., a
balanced diet, physical exercises, and insulin therapy
(Grupo de Estudos em Endocrinologia e Diabetes, 2001).
Because of the countless impositions of treatment, DM is
characterized as one of the most demanding chronic disea-
ses both at the physical and psychological level (Apósto-
lo, Viveiros, Nunes, & Domingues, 2007; Péres, Santos,
Zanetti, & Ferronato, 2007).
In view of the many challenges imposed by the mana-
gement of the disease, over the years DM1 has stimulated
the discovery of many innovations related to treatment
modality (Voltarelli, 2004). In this respect, among the treat-
ments available, Hematopoietic Stem Cell Transplantation
(HSCT) – also known as Bone Marrow Transplantation
(BMT) – has recently arisen as one of the most promising
and bold resources and is being tested as an experimen-
tal alternative to conventional therapy (Couri, Foss, &
Voltarelli, 2006; Couri & Voltarelli, 2008; Voltarelli et
al., 2007).
HSCT as a Treatment Strategy
for Type 1 Diabetes Mellitus
Autologous hematopoietic stem cell transplantation
(HSCT) is used in DM1, with the donor being the patient
himself. His bone marrow is removed during the process
of disease remission and is preserved for later infusion.
Evidence suggests that in DM1, immunosuppression at
high doses associated with infusion of hematopoietic
stem cells can potentially prevent the total destruction
of insulin-producing pancreatic cells, promoting their
preservation. On this basis, pancreatic beta cells would
start again to produce insulin in an efficient manner
(Couri et al., 2006).
At the end of 2002, Brazilian and North American re-
searchers elaborated a pilot protocol of autologous
HSCT for DM1. According to this protocol, patients
younger than 35 years who have been diagnosed with
DM1 for less than six weeks or who are in the asymp-
tomatic phase of the disease are eligible for HSCT
(Voltarelli, 2004).
The procedure consists of various phases. The present
study focused on two of them: pre-HSCT and immediate
post-HSCT period (100 days after HSCT). Phase 1, or
pre-HSCT, involves the pre-admission period, medical
evaluation and patient admission to the ward under pro-
tective isolation. In phase 2, immediate post-HSCT period
(D+100), the patient is seen on an outpatient basis, with
weekly return visits. It is known that the intense restric-
tions imposed by treatment have an impact on the quality
of life of patients with neoplasias and other hematologic
diseases – the main indications of HSCT – but these
restrictions are gradually reduced with time (Mastropietro,
Oliveira, Santos, & Voltarelli, 2007).
During the HSCT procedure, the patients are subjected
to stressful events such as chemotherapy, catheter implan-
tation, waiting for bone marrow to “take” (time when
production of bone marrow cells starts) and the fear of
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contracting infections due to immunosuppression, facts
that contribute to an important impairment of their quality
of life (Riul, 1995). This damage, however, is consistently
attenuated when the patient is discharged from the ward,
with a feeling of optimism after overcoming the critical
period of highest risk of the procedure (Mastropietro et
al., 2007).
Health-Related Quality of Life (HRQoL)
According to Oliveira-Cardoso, Santos, Mastropietro,
and Voltarelli (2009), WHO specialists in quality of life
consider that there are three consensual characteristics in
in the construct of quality of life: subjectivity (a person’s
estimate about his quality of life is not pure, since there
are external conditions present in the environment and in
the living and working conditions that influence it),
bipolarity (the construct has positive dimensions such as
performing social roles, mobility, and autonomy, and
negative ones such as pain, fatigue and dependence, with
emphasis on the perceptions each individual has regar-
ding these dimensions), and multidimensionality (which
includes at least three dimensions, i.e., physical, psy-
chological and social ones, always in the direction of
subjectivity; in other words, what is important is to know
how an individual perceives his physical and affective
status and the interpersonal relations and the social roles
he plays in his life).
In the present investigation, the HRQoL concept was
used, which can be understood as the Perceived Health
Status. This refers to the perception a person has of his
health status when affected or not by some disease
(Ashing-Giwa, 2005; Fayers & Machini, 2007).
As a multidimensional concept, quality of life can be
measured in an objective manner by means of instru-
ments whose properties of reproducibility, validity and
susceptibility to changes are satisfactory (Kovács,
Andrade, & Sgorlon, 1998). In the HRQoL concept,
quality of life is interpreted as a continuum within the
well-being scale that covers domains such as satisfaction,
perception of one’s general health, psychological well-
being and limitations due to the disease itself until death,
with emphasis on the assessment of the subjective well-
being of the patient within the context of his disease,
accident or treatment (Bullinger, Anderson, Cella, &
Aaronson, 1993).
Among the various procedures used to evaluate HRQoL
are generic instruments developed in order to reflect the
impact of a disease on the life of the patients in wide
variety of populations (Ciconelli, 2003). The Generic
Questionnaire for the Assessment of Quality of Life (Me-
dical Outcomes Study 36 Item Short-Form Health Survey
– SF-36) is one of the instruments most frequently used
in the health area all over the world.
This instrument was used in a longitudinal assessment
of HRQoL in 17 patients with serious hematologic disea-
ses submitted to HSCT. The study considered three stages:
pre-HSCT, immediate post-HSCT and late post-HSCT.
The results demonstrated that there was a significant de-
preciation of the quality of life of the patients when thy
left the ward, especially regarding social domains (So-
cial Functioning) and physical domains (Role Limitations
due to Physical Problems). However, a recovery of these
domains and an improvement of others such as Physical
Functioning were observed during the late post-HSCT
period. No significant differences were observed between
the values obtained during the phase preceding the trans-
plant and those obtained one year after the procedure
(Oliveira-Cardoso et al., 2009)
Within the context of the evaluation of autoimmune
diseases, F. A. B. Guimarães, Santos e Oliveira (2008)
assessed 19 patients with autoimmune diseases before and
immediately after HSCT using the generic quality of life
questionnaire SF-36 and detected impairment of HRQoL
domains in patients before HSCT and a recovery of these
indices 100 days after transplantation.
Regarding patients with DM, Aguiar, Vieira, Carvalho,
and Montenegro-Junior (2008) carried out a review of
the literature in order to describe and analyze the generic
and specific instruments for the assessment of quality of
life applied to this population and observed, among other
findings, that the SF-36 is the generic instrument most
frequently used in the various investigations. The validity
and reliability of this scale have been demonstrated in
patients with DM. This is one of the few instruments that
have been formally validated in Brazil. Another advantage
of the SF-36 is that, when compared to specific instru-
ments, it has also been considered appropriate for the
assessment of quality of life in patients with DM.
The conventional treatment of DM delays, but does
not prevent the chronic complications of the disease and
re-quires a rigorous and repeated control of glycemia
along the day. In addition to being difficult to perform,
it is associated with frequent episodes of hypoglyce-
mia. These daily restrictions are responsible for a sig-
nificant impairment of the quality of life of the patients,
a fact that makes it difficult to adhere to treatment, with
a consequent worsening of glycemia control and an
increase in the number of complications due to the
disease (Aguiar et al., 2008; Couri & Voltarelli, 2008;
Rodrigues et al., 2009).
A study conducted on 316 patients with DM1 and DM2
showed that 59.8% of them suffer from the chronic
complications of the disease. Patients with complications
are less satisfied with friends, indicating impairment of
the quality of social interaction (I. Silva et al., 2003).
In view of this evidence and of the lack of Brazilian
as well as international investigations focusing on the
impact of HSCT/BMT on the perception of quality of
life, the objective of the present study was to assess the
health-related quality of life of patients with DM1 sub-
mitted to HSCT.
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Method
Type of Study
The present study can be characterized as a clinical
investigation in which the personal experience of the
investigator is essential for the choice of research subject
and for the execution of the work (Brewer & Hunter, 1989;
Diers, 1979; Miller & Crabtree, 1999, Souza, Cavalcan-
te, Makdisse, & Avezum, 2003).
This is a prospective follow-up study in which the
patients were assessed at two times: pre-HSCT (time
preceding the transplant) and post-HSCT (100 days after
bone marrow infusion).
Participants
The population consisted of 14 patients with DM1 of
both sexes submitted to autologous HSCT at a public
university hospital in the interior of the State of São
Paulo, Brazil, during the period from October 2006 to
December 2007. Inclusion criteria were: being attended
at the outpatient clinics of the BMT Unit before and after
HSCT during the period of evaluation, to be able and
available to collaborate voluntarily with the research, and
to have preservation of cognitive skills.
Table 1
Sample Characterization by Sex, Age, Schooling, Marital Status, and Profession/Occupation
Participant Sex* Age Schooling Marital status Profession/Occupation
1 M 16 High Schoolincomplete Single Student
2 M 20 Higher Educationincomplete Single Military man
3 M 17 High School incomplete Single Student
4 M 27 Higher Educationcomplete Casado Nursing Technician
5 M 16 High Schoolincomplete Single Student
6 F 24 Higher Educationincomplete Single Secretary
7 M 16 High School incomplete Single Student
8 F 18 Higher Educationincomplete Single Student
9 F 17 High Schoolcomplete Single Student
10 M 16 High Schoolincomplete Single Student
11 F 14 High Schoolincomplete Single Student
12 M 24 Higher Education complete Single Biologist
13 M 31 Higher Educationcomplete Married Dentist
14 M 16 High School incomplete Single Student
Note. * M: Male; F: Female.
Table 1 shows that 10 of the 14 patients were males.
Age ranged from 14 to 31 years (mean = 19.43 years;
standard deviation = 5.07). Eight participants were High
School students at the time of assessment; 12 were single
and two were married. Most participants were students, a
fact compatible with the juvenile range of the population
investigated and with the time in the life cycle when the
diagnosis is established. The older participants had pro-
fessions or occupations such as military man, nursing
technician, secretary, biologist, and dentist.
Instrument
Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36). The SF-36 is a multimensional instrument
for the generic assessment of health originally elaborated
in the English language, which is easy to administer and
to understand. It consists of 36 questions covering eight
domains that can be grouped into Physical Components
and Mental Components (Ware, Kosinski, & Keller, 1994).
According to Ciconelli (2003), the results of each dimen-
sion range from 0 to 100. In this continuum, 0 corresponds
to the worst health status and 100 to the best health status.
Internal consistency was determined according to the
Cronbach alpha, which exceeded .90 for all domains. In
addition to having appropriate psychometric properties,
the SF-36 is an instrument widely used all over the world,
permitting comparison with results obtained in other stu-
dies with similar samples.
A version of this scale for the Portuguese language was
developed after a translation and transcultural adaptation
process, which confirmed its measuring properties, i.e.,
reproducibility and validity. The study concluded that this
instrument is a reproducible and valid parameter to be
used for the evaluation of the HRQoL of Brazilian patients
with chronic diseases (Ciconelli, 2003).
The SF-36 measures the basic human necessities and
the emotional and functional well-being (Ware & Sher-
bourne, 1992). Like all quality of life scales, it provides
an estimate of subjective satisfaction in different domains.
Several studies using this instrument have been published
in the specific literature about HSCT (Hann, Jacobsen,
Martin, Kronish, & Azzarello, 1997; Mastropietro, Car-
Psicologia: Reflexão e Crítica, 24(2), 264-271.
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doso-Oliveira, Santos, & Voltarelli, 2009; Mastropietro
et al., 2007; L. M. G. Silva, 2000; Sutherland et al., 1997).
Data Collection
Ethical Considerations. The research Project was
approved by the Research Ethics Committee of the Uni-
versity Hospital (protocol nº 7673/2006). The study
insured the ethical care that guarantees the integrity of
the participant according to the directives and norms
defined by Resolution nº 196/96 to regulate research
involving human beings (Conselho Nacional de Saúde,
1996) and by Resolution nº 196 of the Federal Council of
Psychology (2000).
Application of the Instrument. The instrument was
applied individually to each patient upon admission and
reapplied on the occasion of the ambulatory return visit
100 days after HSCT. The instrument was applied with
the help of the investigator, who only read the questions
individually, without the presence of the parents or
persons responsible. The first application occurred on
the ward of the HSCT Unit and the second in a room of
the outpatient clinic. The mean time of application was
40 minutes.
Data Analysis. The instrument was evaluated according
to the directions of Ciconelli (2003). After application, a
score was attributed to each question and later transfor-
med on a scale from 0 to 100. As mentioned earlier, zero
corresponds to a worse health condition and 100 to a better
condition, with each dimension being analyzed separately.
Purposely, there is no general value in view of the
multidimensional character of the HRQoL construct.
Data were analyzed statistically by the Wilcoxon test
for paired samples, with the level of significance set at
p < .05.
Results and Discussion
The mean values of the results obtained with the appli-
cation of the quality of life questionnaire (SF-36) before
and after transplantation are summarized in Table 2.
Table 2
Means, Standard Deviations and Probability of the SF-36 Variables Determined by the Wilcoxon Test in the Group (N
= 14) Before and After HSCT
Physical and Mental Components of SF-36          Pre-BMT              SD             Post-BMT          SD p
Physical Functioning 93.57 11.34 95.71 8.52 .40
Role Limitations due to Physical Problems      41.07 36.17 81.93 17.58 .009*
Bodily Pain 68.50 26.60 82.64 12.40 .16
General Health Perceptions 75.07 12.17 84.79 12.08 .10
Vitality 63.57 18.23 76.07 11.30 .02*
Social Functioning 59.82 34.03 80.00 22.45 .12
Role Limitations due to Emotional Problems 71.43 43.10 84.57 23.08 .31
General Mental Health 66.86 9.34 74.57 13.28 .04*
Note. * p< .05.
The domains most affected during the period before
HSCT were the Role Limitations due to Physical Problems
and Social Functioning. The Role Limitations due to
Physical Problems were evaluated with items of the
questionnaire that score difficulties in executing physical
activities due to the transplant, i.e. “vigorous activities
that require great effort such as running, lifting heavy
objects, participating in strenuous sports” and “moderate
activities such as moving a table, vacuuming the floor,
playing ball, sweeping the house”. At the first evaluation,
the physical health of all participants was compromised
not only by the restriction of the environment due to
hospitalization, but also by the metabolic changes due to
the lack of stabilization of the disease a short time after
the diagnosis (Damião & Pinto, 2007). At the second
evaluation, the improvement of these indicators of quality
of life reflected the restoration of the physical conditions,
one of the objectives of HSCT.
The Mental Health component estimates the perception
the patient has of his own emotional equilibrium and his
resistance over time, with items such as: “how long have
you felt like a very nervous person?”, “how long have
you felt so depressed that nothing could cheer you up?”.
The significant increase in the score attributed to this
component suggests a better emotional control, with a
reduction of the signs and symptoms of anxiety and
depression. It is possible to postulate that there was a
recovery of psychological stability, which had been tem-
porarily affected by the orders received after learning
about the diagnosis (Zanetti et al., 2008), by the daily
limitations caused by the disease (Santos & Enumo, 2003),
and especially by the perspective of having to face the
challenges of HSCT (Oliveira-Cardoso et al., 2009).
Statistical analysis of the data revealed a significant
increase in the scores of the following domains related to
the quality of life of the participants 100 days after the
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HSCT: Role Limitations due to Physical Problems (p =
.009), Mental Health (p = .04), and Vitality (p = .02).
The Vitality domain is assessed by items such as: “how
long have you felt full of vigor, full of desire, full of
strength?”, “how long have you felt a lot of energy?”.
The better appreciation of this domain during the post-
HSCT phase reflects the gradual recovery of the patient,
who had to go through a stressful period both from a
physical and psychological viewpoint (F. A. B. Guima-
rães et al., 2008). During the transplant the patients are
exposed to various stressful events which contribute to a
marked impairment of their quality of life (Riul, 1995).
Discharge from the ward favors the recovery of optimism
on the part of the patient by having overcome the critical
and highest risk stage of the procedure and by the pers-
pective of leaving the protective isolation (Mastropietro
et al., 2007). This increases the sensation of well-being
and of control of the events of one’s life, which had been
seriously compromised during the experience of admis-
sion, with invasive procedures and serious immuno-
suppression.
To understand why an improvement in quality of life
occurs 100 days after transplantation, i.e. at the second
time of assessment, it is important to consider that the
patients had already returned home and their ambulatory
return visits for medical follow-up were being increasin-
gly spaced, a fact that possibly reduced the sensation of
dependence on the hospital and on the health multidis-
ciplinary team.
An improvement of quality of life immediately after
HSCT was observed by F. A. B. Guimarães et al. (2008).
These authors evaluated patients with autoimmune
diseases before and immediately after HSCT and detec-
ted impairment of quality of life domains in the patients
before the transplant, followed by a recovery of these
indices 100 days after the procedure.
An encouraging result is the rapid recovery of HRQoL
by patients with DM compared to patients with other
diseases also submitted to HSCT. According to Oliveira-
Cardoso et al. (2009), a significant depreciation of quality
of life is observed in the patients during the immediate
post-HSCT period, especially in social domains (Social
Functioning) and in physical domains (Role Limitations
due to Physical Problems). According to the cited study,
the recovery of these domains of the HRQoL and the
improvement of others such as Physical Functioning
occurred during the late post-HSCT period, i.e., one year
after the procedure.
It should be pointed out that, in the present investigation,
the patients had been living, even for a short time, with
the limitations of a chronic disease such as DM1 and had
the opportunity to intervene early in the course of the
condition. This possibility of controlling a progressive
and debilitating morbid condition opened entirely new
perspectives for these patients, a fact that appeared to be
essential for the improvement of the patterns of quality
of life assessed with the instrument used.
Final Considerations
The SF-36, the instrument used to measure the quality
of life of patients with DM1, proved to be appropriate for
the purposes of the present investigation. Easily and
rapidly applied, the instrument was well accepted by the
participants, providing data that were consistent with the
objectives of the present study.
On the basis of the present results, we perceive that,
despite all the difficulties faced by these young patients
over such a short period of time, the hope for a resolving
treatment of DM1 and the perspective of a future free of
the disease or with attenuated disease manifestations
reduces the fear of future complications. Thus, favorable
expectations regarding the outcome of the procedure may,
of themselves, contribute to improving the quality of life.
Despite the limitation of the present study in terms of
generalization of the data due to the small sample size,
the originality of the investigation and its innovative
nature at the international level endorse the dissemination
of the results. It should be remembered that the treatment
in question is a pioneer one in the world and is regulated
by an experimental protocol that is being tested, a fact
that explains the reduced number of cases evaluated up
to now.
Due to the recent beginning of hematopoietic stem cell
transplantation for patients with DM1 and to the small
number of subjects transplanted thus far, it is essential to
conduct more investigations that will compare the quality
of life of those who live with the disease to the quality of
life of those who receive the transplant, so that the effects
of the procedure on the recipients may be estimated. In
addition, follow-up studies of greater amplitude are
desirable in order to examine whether the improvement
in quality of life observed on a short-term basis will tend
to persist over time. Thus, it will be possible to monitor
the course of this innovative treatment and to examine
the evolution of the patients starting from promising initial
results.
By dealing with a multidimensional construct, investi-
gation with the HRQoL may contribute to the enrichment
of various disciplines in the health field, including
Psychology, Medicine and Nursing. Since the research
protocol regarding the applicability of HSCT to DM1 is
part of a multicenter study in which Brazil is one of the
participating countries, this study may represent a sig-
nificant advance for Brazilian Psychology.
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